ArticleBreast cancer research and treatment2018

The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.

Virginie Ory et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.